Sam Brusco, Associate Editor12.20.23
Henry Schein, a provider of healthcare solutions to office-based dental and medical clinicians, acquired majority interest in TriMed and began a strategic relationship with Extremity Medical.
TriMed serves the orthopedic extremity treatment market as a maker of hand, wrist, foot, and ankle surgery devices. The company is based in Santa Clarita, Calif. and generated 2022 revenues of abut $48 million. Henry Schein expects this transaction to be completed in Q1 2024.
Extremity Medical is also focused on the orthopedic extremities market—the company develops products for fusion, fixation, and motion preservation in the lower extremities and wrist. Extremity is located in Parsippany, N.J. and will remain a separate, standalone company.
“We believe the experienced leadership team that we have assembled is well-positioned to leverage our deep and longstanding relationships with existing integrated delivery network and ambulatory surgery center customers,” said Henry Schein chairman and CEO Stanley M. Bergman.
TriMed founders David Medoff (chief commercial officer) and Robert Medoff, MD (medical advisor) will continue to be a part of TriMed’s management team.
“TriMed provides unique treatment options for challenging indications and injuries. Henry Schein will help to accelerate our growth and increase our reach within the medical community,” said Medoff.
“We are looking forward to entering the extremity segment with the complementary portfolios of TriMed and Extremity Medical, which extend our Brasseler Medical orthopedic cutting accessories and revision instrument solutions,” added Tom Popeck, president of Henry Schein’s Healthcare Specialties Group. “Upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion. We are confident that we will accelerate the reach of TriMed and Extremity on a global basis.”
TriMed serves the orthopedic extremity treatment market as a maker of hand, wrist, foot, and ankle surgery devices. The company is based in Santa Clarita, Calif. and generated 2022 revenues of abut $48 million. Henry Schein expects this transaction to be completed in Q1 2024.
Extremity Medical is also focused on the orthopedic extremities market—the company develops products for fusion, fixation, and motion preservation in the lower extremities and wrist. Extremity is located in Parsippany, N.J. and will remain a separate, standalone company.
“We believe the experienced leadership team that we have assembled is well-positioned to leverage our deep and longstanding relationships with existing integrated delivery network and ambulatory surgery center customers,” said Henry Schein chairman and CEO Stanley M. Bergman.
TriMed founders David Medoff (chief commercial officer) and Robert Medoff, MD (medical advisor) will continue to be a part of TriMed’s management team.
“TriMed provides unique treatment options for challenging indications and injuries. Henry Schein will help to accelerate our growth and increase our reach within the medical community,” said Medoff.
“We are looking forward to entering the extremity segment with the complementary portfolios of TriMed and Extremity Medical, which extend our Brasseler Medical orthopedic cutting accessories and revision instrument solutions,” added Tom Popeck, president of Henry Schein’s Healthcare Specialties Group. “Upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion. We are confident that we will accelerate the reach of TriMed and Extremity on a global basis.”